These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 29137590)

  • 21. Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
    Kalafateli M; Dusheiko G; Manousou P
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):257-8. PubMed ID: 26114189
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience.
    Hlaing NKT; Mitrani RA; Aung ST; Phyo WW; Serper M; Kyaw AMM; Bwa AH; Win KM; Reddy KR
    J Viral Hepat; 2017 Nov; 24(11):927-935. PubMed ID: 28475232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
    Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
    Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
    Harada N; Yoshizumi T; Ikegami T; Itoh S; Furusho N; Kato M; Shimoda S; Fukuhara T; Soejima Y; Maehara Y
    Anticancer Res; 2018 Sep; 38(9):5513-5520. PubMed ID: 30194210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
    Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
    Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
    Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.
    Pott-Junior H; Bricks G; Grandi G; Figueiredo Senise J; Castelo Filho A
    Clin Microbiol Infect; 2019 Mar; 25(3):365-371. PubMed ID: 29906601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
    Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
    Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.
    Xue Y; Zhang LX; Wang L; Li T; Qu YD; Liu F
    World J Gastroenterol; 2017 Aug; 23(32):5969-5976. PubMed ID: 28932089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
    Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP
    Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
    Jackson WE; Hanouneh M; Apfel T; Alkhouri N; John BV; Zervos X; Zein NN; Hanouneh IA
    Clin Transplant; 2016 Jun; 30(6):709-13. PubMed ID: 27019204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
    Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
    Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy for hepatitis C genotype 3: moving forward.
    Buti M; Llaneras J; Riveiro-Barciela M; Esteban R
    J Viral Hepat; 2015 Sep; 22(9):683-90. PubMed ID: 25967352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
    El-Khayat H; Fouad Y; Mohamed HI; El-Amin H; Kamal EM; Maher M; Risk A
    Aliment Pharmacol Ther; 2018 Mar; 47(5):674-679. PubMed ID: 29314146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.
    Smith MA; Regal RE; Mohammad RA
    Ann Pharmacother; 2016 Jan; 50(1):39-46. PubMed ID: 26486762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.